Metagenome-assembled genome: ERR1190932_bin.34_CONCOCT_v1.1_MAG
uncultured Acidaminococcus sp.
This sample represents a Third Party Annotation (TPA) Metagenome-Assembled Genome (MAG) assembled from the metagenomic run ERR1190932 of study ERP013563.
ENA-FIRST-PUBLIC
2023-01-03
ENA-LAST-UPDATE
2023-01-03
External Id
SAMEA14083396
INSDC center alias
EBI
INSDC center name
European Bioinformatics Institute
INSDC first public
2023-01-03T00:33:30Z
INSDC last update
2023-01-03T00:33:30Z
INSDC status
public
Submitter Id
ERR1190932_bin.34_CONCOCT_v1.1_MAG
assembly quality
Many fragments with little to no review of assembly other than reporting of standard assembly statistics
assembly software
spades_v3.11.1
binning parameters
Default
binning software
CONCOCT v1.1
broker name
EMG broker account, EMBL-EBI
collection date
2014-01-01
completeness score
100
completeness software
CheckM
contamination score
0.0
environment (biome)
Host-associated
environment (feature)
Human
environment (material)
Digestive system
geographic location (country and/or sea)
China
geographic location (latitude)
55.676098
geographic location (longitude)
12.568337
investigation type
metagenome-assembled genome
isolation_source
human gut metagenome
metagenomic source
human gut metagenome
project name
Dysbosis of intestinal microbiota could contribute to the pathogenesis of Type 2 Diabetes. It is yet to be known whether intestinal flora could be related to differential responds to antidiabetic therapies. This study, herein for the first time, metagenomic sequenced fecal samples from a randomized clinical trial on new onset untreated Type 2 Diabetes patients applied two treatment arms, Acarbose and Glipizide (Sulfonylurea) and analyzed the differential responses of intestinal flora in different groups. Results showed substantial impact of Acarbose on gut microbiota community but minor of Glipizide. Enterotypes with similar baseline clinical characteristics, had significant different pharmacologic respond to Acarbose on insulin resistance, gut hormones, bile acids and cardiovascular risks, indicating that different pattern of intestinal microbiota component could determine different responses of Type 2 Diabetes to antidiabetic pharmacological therapies.
sample derived from
SAMEA3708858
sample name
ERR1190932_bin.34_CONCOCT_v1.1_MAG
scientific_name
uncultured Acidaminococcus sp.
sequencing method
Illumina HiSeq 2500
taxonomic identity marker
multi-marker approach